SI3773689T1 - Antigenski peptidi za preprečevanje in zdravljenje raka - Google Patents
Antigenski peptidi za preprečevanje in zdravljenje rakaInfo
- Publication number
- SI3773689T1 SI3773689T1 SI201930437T SI201930437T SI3773689T1 SI 3773689 T1 SI3773689 T1 SI 3773689T1 SI 201930437 T SI201930437 T SI 201930437T SI 201930437 T SI201930437 T SI 201930437T SI 3773689 T1 SI3773689 T1 SI 3773689T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cancer
- prevention
- treatment
- antigenic peptides
- antigenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305444 | 2018-04-11 | ||
| EP2018077512 | 2018-10-09 | ||
| PCT/EP2019/059329 WO2019197567A2 (en) | 2018-04-11 | 2019-04-11 | Antigenic peptides for prevention and treatment of cancer |
| EP19716176.3A EP3773689B1 (en) | 2018-04-11 | 2019-04-11 | Antigenic peptides for prevention and treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3773689T1 true SI3773689T1 (sl) | 2023-02-28 |
Family
ID=66092357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930437T SI3773689T1 (sl) | 2018-04-11 | 2019-04-11 | Antigenski peptidi za preprečevanje in zdravljenje raka |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12016910B2 (https=) |
| EP (2) | EP3773689B1 (https=) |
| JP (2) | JP7384819B2 (https=) |
| CN (2) | CN120535570A (https=) |
| AU (1) | AU2019253217B2 (https=) |
| BR (1) | BR112020020780A2 (https=) |
| CA (1) | CA3094262A1 (https=) |
| DK (1) | DK3773689T5 (https=) |
| ES (1) | ES2935702T3 (https=) |
| FI (1) | FI3773689T3 (https=) |
| HR (1) | HRP20230007T1 (https=) |
| HU (1) | HUE060791T2 (https=) |
| LT (1) | LT3773689T (https=) |
| MX (2) | MX2020010701A (https=) |
| PL (1) | PL3773689T3 (https=) |
| RS (1) | RS63873B1 (https=) |
| SI (1) | SI3773689T1 (https=) |
| SM (1) | SMT202300021T1 (https=) |
| WO (1) | WO2019197567A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| WO2018065623A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Immunogenic compounds for cancer therapy |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| MX2022004598A (es) * | 2019-10-16 | 2022-09-23 | Enterome S A | Compuestos inmunogenicos para el tratamiento del cancer suprarrenal. |
| FI4021487T3 (fi) * | 2019-11-15 | 2024-02-06 | Enterome S A | Antigeenisiä peptidejä b-solun pahanlaatuisuuden ehkäisyyn ja hoitoon |
| CN111197040B (zh) * | 2020-01-21 | 2023-08-08 | 福建亿彤生物科技有限公司 | 壳多糖酶3样蛋白1（chi3l1）抗原表位肽、抗原、抗体、用途及试剂盒 |
| CN114163511B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
| AU2023246941A1 (en) * | 2022-03-31 | 2024-10-24 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer. |
| IT202200006785A1 (it) * | 2022-04-06 | 2023-10-06 | Istituto Naz Tumori Irccs Fondazione G Pascale | Analoghi di antigeni tumorali da microbiota e usi relativi |
| KR20240017325A (ko) * | 2022-07-29 | 2024-02-07 | 주식회사 엘지화학 | 항원 전달용 재조합 융합 단백질 및 이의 이용 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| ATE459373T1 (de) | 1999-03-19 | 2010-03-15 | Glaxosmithkline Biolog Sa | Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae |
| ATE512666T1 (de) | 1999-06-29 | 2011-07-15 | Epimmune Inc | Hla-bindende peptide und ihre verwendungen |
| FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| CA2400215A1 (en) | 2000-02-23 | 2001-08-30 | Epimmune Inc. | Hla binding peptides and their uses |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| WO2003092717A1 (en) | 2002-03-22 | 2003-11-13 | The Penn State Research Foundation | Cancer immunotherapy |
| CA2500715A1 (en) | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Hla binding peptides and their uses |
| CN1954217B (zh) | 2004-02-06 | 2013-05-08 | 国立健康与医学研究所 | 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途 |
| US7612162B2 (en) | 2004-09-21 | 2009-11-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| BRPI0720280A2 (pt) | 2006-12-11 | 2014-01-28 | Wyeth Corp | Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13 |
| US8569244B2 (en) * | 2007-08-20 | 2013-10-29 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
| ES2532896T5 (es) | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| WO2010018136A1 (en) | 2008-08-12 | 2010-02-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| TWI469791B (zh) | 2009-02-18 | 2015-01-21 | Oncotherapy Science Inc | Ｆｏｘｍ１胜肽以及含此胜肽之疫苗 |
| WO2010129033A2 (en) | 2009-04-29 | 2010-11-11 | Calmune Corporation | Modified antibodies for passive immunotherapy |
| KR101276180B1 (ko) * | 2009-11-03 | 2013-06-18 | 고려대학교 산학협력단 | 산화아연-결합성 펩타이드를 포함하는 단백질과 산화아연 나노입자의 복합체 및 그의 용도 |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| CA2809362C (en) | 2010-08-24 | 2020-03-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| WO2013101690A1 (en) | 2011-12-29 | 2013-07-04 | modeRNA Therapeutics | Modified mrnas encoding cell-penetrating polypeptides |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| EP2828664B1 (en) | 2012-03-19 | 2018-09-26 | Stemline Therapeutics Inc. | Methods for treating and monitoring the status of cancer |
| WO2013148147A1 (en) | 2012-03-26 | 2013-10-03 | The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services | Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| CA3183703A1 (en) | 2012-05-16 | 2013-11-21 | Stemline Therapeutics, Inc. | Cancer stem cell targeted cancer vaccines |
| US20140141044A1 (en) | 2012-11-12 | 2014-05-22 | Dana-Farber Cancer Institute, Inc. | Cord Colitis Syndrome Pathogen |
| US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
| WO2014088432A1 (en) | 2012-12-06 | 2014-06-12 | Callaghan Innovation Research Limited | Conjugate compounds |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| SG10202005892SA (en) * | 2014-06-06 | 2020-07-29 | Herlev Hospital | Determining antigen recognition through barcoding of mhc multimers |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| US20180078627A1 (en) | 2015-03-31 | 2018-03-22 | Agency For Science, Technology And Research | Method for antigen loading of dendritic cells and vaccine |
| BR112018005581A2 (pt) | 2015-10-08 | 2018-10-16 | Oncotherapy Science, Inc. | peptídeo derivado de foxm1 e vacina incluindo o mesmo |
| US12018331B2 (en) | 2016-05-23 | 2024-06-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of diagnosing cancer using cancer testis antigens |
| WO2018065623A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Immunogenic compounds for cancer therapy |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| KR102823291B1 (ko) | 2017-10-09 | 2025-06-19 | 엔터롬 에스.에이. | 종양-관련된 항원 에피토프의 미생물 서열 변이체 |
| US20210106652A1 (en) | 2018-04-11 | 2021-04-15 | Enterome S.A. | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation |
| MX2022004598A (es) | 2019-10-16 | 2022-09-23 | Enterome S A | Compuestos inmunogenicos para el tratamiento del cancer suprarrenal. |
| FI4021487T3 (fi) | 2019-11-15 | 2024-02-06 | Enterome S A | Antigeenisiä peptidejä b-solun pahanlaatuisuuden ehkäisyyn ja hoitoon |
-
2019
- 2019-04-11 HR HRP20230007TT patent/HRP20230007T1/hr unknown
- 2019-04-11 RS RS20230005A patent/RS63873B1/sr unknown
- 2019-04-11 EP EP19716176.3A patent/EP3773689B1/en active Active
- 2019-04-11 DK DK19716176.3T patent/DK3773689T5/da active
- 2019-04-11 BR BR112020020780-2A patent/BR112020020780A2/pt unknown
- 2019-04-11 MX MX2020010701A patent/MX2020010701A/es unknown
- 2019-04-11 EP EP22201142.1A patent/EP4169528A1/en active Pending
- 2019-04-11 HU HUE19716176A patent/HUE060791T2/hu unknown
- 2019-04-11 SI SI201930437T patent/SI3773689T1/sl unknown
- 2019-04-11 FI FIEP19716176.3T patent/FI3773689T3/fi active
- 2019-04-11 PL PL19716176.3T patent/PL3773689T3/pl unknown
- 2019-04-11 JP JP2020555892A patent/JP7384819B2/ja active Active
- 2019-04-11 SM SM20230021T patent/SMT202300021T1/it unknown
- 2019-04-11 CN CN202510612435.XA patent/CN120535570A/zh active Pending
- 2019-04-11 CA CA3094262A patent/CA3094262A1/en active Pending
- 2019-04-11 ES ES19716176T patent/ES2935702T3/es active Active
- 2019-04-11 CN CN201980032574.8A patent/CN112118863B/zh active Active
- 2019-04-11 WO PCT/EP2019/059329 patent/WO2019197567A2/en not_active Ceased
- 2019-04-11 AU AU2019253217A patent/AU2019253217B2/en active Active
- 2019-04-11 LT LTEPPCT/EP2019/059329T patent/LT3773689T/lt unknown
- 2019-04-11 US US17/043,192 patent/US12016910B2/en active Active
-
2020
- 2020-10-09 MX MX2023014457A patent/MX2023014457A/es unknown
-
2023
- 2023-11-09 JP JP2023191203A patent/JP7670445B2/ja active Active
-
2024
- 2024-05-03 US US18/654,304 patent/US20240293520A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12016910B2 (en) | 2024-06-25 |
| MX2023014457A (es) | 2023-12-15 |
| CN120535570A (zh) | 2025-08-26 |
| CA3094262A1 (en) | 2019-10-17 |
| HUE060791T2 (hu) | 2023-04-28 |
| PL3773689T3 (pl) | 2023-03-13 |
| DK3773689T3 (da) | 2023-01-16 |
| EP4169528A1 (en) | 2023-04-26 |
| SMT202300021T1 (it) | 2023-03-17 |
| JP7384819B2 (ja) | 2023-11-21 |
| EP3773689B1 (en) | 2022-11-09 |
| US20240293520A1 (en) | 2024-09-05 |
| ES2935702T3 (es) | 2023-03-09 |
| FI3773689T3 (fi) | 2023-01-31 |
| US20210113678A1 (en) | 2021-04-22 |
| CN112118863A (zh) | 2020-12-22 |
| CN112118863B (zh) | 2025-05-30 |
| HRP20230007T1 (hr) | 2023-03-03 |
| MX2020010701A (es) | 2021-01-20 |
| WO2019197567A3 (en) | 2019-11-28 |
| BR112020020780A2 (pt) | 2021-03-02 |
| LT3773689T (lt) | 2023-01-25 |
| JP7670445B2 (ja) | 2025-04-30 |
| JP2024016203A (ja) | 2024-02-06 |
| AU2019253217B2 (en) | 2025-09-25 |
| DK3773689T5 (da) | 2024-08-19 |
| RS63873B1 (sr) | 2023-02-28 |
| JP2021520818A (ja) | 2021-08-26 |
| WO2019197567A2 (en) | 2019-10-17 |
| AU2019253217A1 (en) | 2020-10-15 |
| EP3773689A2 (en) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3773689T3 (pl) | Peptydy antygenowe do zapobiegania i leczenia raka | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| IL255333A0 (en) | Vaccines for the treatment and prevention of cancer | |
| IL276808A (en) | Preparations and methods for the treatment of cancer | |
| IL279347A (en) | Gremlin-1 antagonist for cancer prevention and treatment | |
| HUE065075T2 (hu) | Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére | |
| SG11202011117VA (en) | Treatment of cancer | |
| SG11202006160RA (en) | Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer | |
| IL286297A (en) | Minimal residual cancer treatment methods | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| IL280468A (en) | Secondary vaccine particles for cancer treatment | |
| GB201812647D0 (en) | Viral vectors and methods for the prevention or treatment of cancer | |
| SI3630112T1 (sl) | Kombinacija regorafeniba in nivolumaba za zdravljenje raka | |
| IL281782A (en) | Drug combination for cancer treatment | |
| GB201810635D0 (en) | Peptides and cancer treatment | |
| GB201820098D0 (en) | Methods of cancer treatment | |
| SG11202000724XA (en) | Methods and compositions for the treatment of cancer | |
| IL288433A (en) | Peroxidase-3 activation and immunotherapy for cancer treatment | |
| IL280262A (en) | Compositions and methods for treating cancer | |
| IL277313A (en) | Sposin C Pharmaceuticals and Cancer Treatment Methods | |
| GB201820975D0 (en) | Methods of cancer treatment | |
| PT4021487T (pt) | Péptidos antigénicos para prevenir e tratar neoplasia maligna de células b | |
| GB201815694D0 (en) | Prevention and treatment of cancer | |
| GB201809946D0 (en) | Prevention and treatment of cancer | |
| SG11202101945PA (en) | Peptide therapeutics for the treatment of cancer and uses thereof |